John T Wei1, Ziding Feng2, Alan W Partin2, Elissa Brown2, Ian Thompson2, Lori Sokoll2, Daniel W Chan2, Yair Lotan2, Adam S Kibel2, J Erik Busby2, Mohamed Bidair2, Daniel W Lin2, Samir S Taneja2, Rosalia Viterbo2, Aron Y Joon2, Jackie Dahlgren2, Jacob Kagan2, Sudhir Srivastava2, Martin G Sanda2. 1. John T. Wei, University of Michigan, Ann Arbor, MI; Ziding Feng, Elissa Brown, Aron Y. Joon, Jackie Dahlgren, Fred Hutchinson Cancer Research Center; Daniel W. Lin, University of Washington, Seattle, WA; Alan W. Partin, Lori Sokoll, Daniel W. Chan, Johns Hopkins University, Baltimore; Jacob Kagan, Sudhir Srivastava, National Cancer Institute, Bethesda, MD; Ian Thompson, The University of Texas San Antonio, San Antonio; Yair Lotan, The University of Texas Southwestern Medical Center, Dallas, TX; Adam S. Kibel, Harvard University, Cambridge; Martin G. Sanda, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; J. Erik Busby, University of South Carolina, Greenville, SC; Mohamed Bidair, San Diego Clinical Trials, San Diego, CA; Samir S. Taneja, New York University, New York, NY; and Rosalia Viterbo, Fox Chase Cancer Center, Philadelphia, PA. jtwei@umich.edu. 2. John T. Wei, University of Michigan, Ann Arbor, MI; Ziding Feng, Elissa Brown, Aron Y. Joon, Jackie Dahlgren, Fred Hutchinson Cancer Research Center; Daniel W. Lin, University of Washington, Seattle, WA; Alan W. Partin, Lori Sokoll, Daniel W. Chan, Johns Hopkins University, Baltimore; Jacob Kagan, Sudhir Srivastava, National Cancer Institute, Bethesda, MD; Ian Thompson, The University of Texas San Antonio, San Antonio; Yair Lotan, The University of Texas Southwestern Medical Center, Dallas, TX; Adam S. Kibel, Harvard University, Cambridge; Martin G. Sanda, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; J. Erik Busby, University of South Carolina, Greenville, SC; Mohamed Bidair, San Diego Clinical Trials, San Diego, CA; Samir S. Taneja, New York University, New York, NY; and Rosalia Viterbo, Fox Chase Cancer Center, Philadelphia, PA.
Abstract
PURPOSE: Given the limited sensitivity and specificity of prostate-specific antigen (PSA), its widespread use as a screening tool has raised concerns for the overdiagnosis of low-risk and the underdiagnosis of high-grade prostate cancer. To improve early-detection biopsy decisions, the National Cancer Institute conducted a prospective validation trial to assess the diagnostic performance of the prostate cancer antigen 3 (PCA3) urinary assay for the detection of prostate cancer among men screened with PSA. PATIENTS AND METHODS: In all, 859 men (mean age, 62 years) from 11 centers scheduled for a diagnostic prostate biopsy between December 2009 and June 2011 were enrolled. The primary outcomes were to assess whether PCA3 could improve the positive predictive value (PPV) for an initial biopsy (at a score > 60) and the negative predictive value (NPV) for a repeat biopsy (at a score < 20). RESULTS: For the detection of any cancer, PPV was 80% (95% CI, 72% to 86%) in the initial biopsy group, and NPV was 88% (95% CI, 81% to 93%) in the repeat biopsy group. The addition of PCA3 to individual risk estimation models (which included age, race/ethnicity, prior biopsy, PSA, and digital rectal examination) improved the stratification of cancer and of high-grade cancer. CONCLUSION: These data independently support the role of PCA3 in reducing the burden of prostate biopsies among men undergoing a repeat prostate biopsy. For biopsy-naive patients, a high PCA3 score (> 60) significantly increases the probability that an initial prostate biopsy will identify cancer.
RCT Entities:
PURPOSE: Given the limited sensitivity and specificity of prostate-specific antigen (PSA), its widespread use as a screening tool has raised concerns for the overdiagnosis of low-risk and the underdiagnosis of high-grade prostate cancer. To improve early-detection biopsy decisions, the National Cancer Institute conducted a prospective validation trial to assess the diagnostic performance of the prostate cancer antigen 3 (PCA3) urinary assay for the detection of prostate cancer among men screened with PSA. PATIENTS AND METHODS: In all, 859 men (mean age, 62 years) from 11 centers scheduled for a diagnostic prostate biopsy between December 2009 and June 2011 were enrolled. The primary outcomes were to assess whether PCA3 could improve the positive predictive value (PPV) for an initial biopsy (at a score > 60) and the negative predictive value (NPV) for a repeat biopsy (at a score < 20). RESULTS: For the detection of any cancer, PPV was 80% (95% CI, 72% to 86%) in the initial biopsy group, and NPV was 88% (95% CI, 81% to 93%) in the repeat biopsy group. The addition of PCA3 to individual risk estimation models (which included age, race/ethnicity, prior biopsy, PSA, and digital rectal examination) improved the stratification of cancer and of high-grade cancer. CONCLUSION: These data independently support the role of PCA3 in reducing the burden of prostate biopsies among men undergoing a repeat prostate biopsy. For biopsy-naive patients, a high PCA3 score (> 60) significantly increases the probability that an initial prostate biopsy will identify cancer.
Authors: M J Bussemakers; A van Bokhoven; G W Verhaegh; F P Smit; H F Karthaus; J A Schalken; F M Debruyne; N Ru; W B Isaacs Journal: Cancer Res Date: 1999-12-01 Impact factor: 12.701
Authors: H B Carter; J D Pearson; E J Metter; L J Brant; D W Chan; R Andres; J L Fozard; P C Walsh Journal: JAMA Date: 1992 Apr 22-29 Impact factor: 56.272
Authors: Daphne Hessels; Jacqueline M T Klein Gunnewiek; Inge van Oort; Herbert F M Karthaus; Geert J L van Leenders; Bianca van Balken; Lambertus A Kiemeney; J Alfred Witjes; Jack A Schalken Journal: Eur Urol Date: 2003-07 Impact factor: 20.096
Authors: Scott E Eggener; Ketan Badani; Daniel A Barocas; Glen W Barrisford; Jed-Sian Cheng; Arnold I Chin; Anthony Corcoran; Jonathan I Epstein; Arvin K George; Gopal N Gupta; Matthew H Hayn; Eric C Kauffman; Brian Lane; Michael A Liss; Moben Mirza; Todd M Morgan; Kelvin Moses; Kenneth G Nepple; Mark A Preston; Soroush Rais-Bahrami; Matthew J Resnick; M Minhaj Siddiqui; Jonathan Silberstein; Eric A Singer; Geoffrey A Sonn; Preston Sprenkle; Kelly L Stratton; Jennifer Taylor; Jeffrey Tomaszewski; Matt Tollefson; Andrew Vickers; Wesley M White; William T Lowrance Journal: J Urol Date: 2015-04-04 Impact factor: 7.450
Authors: Donna P Ankerst; Martin Goros; Scott A Tomlins; Dattatraya Patil; Ziding Feng; John T Wei; Martin G Sanda; Jonathan Gelfond; Ian M Thompson; Robin J Leach; Michael A Liss Journal: Eur Urol Focus Date: 2018-02-13
Authors: Jennifer A Sinnott; Sam F Peisch; Svitlana Tyekucheva; Travis Gerke; Rosina Lis; Jennifer R Rider; Michelangelo Fiorentino; Meir J Stampfer; Lorelei A Mucci; Massimo Loda; Kathryn L Penney Journal: Clin Cancer Res Date: 2016-09-23 Impact factor: 12.531